FindTrial
Sign In

BI 10773 high dose

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2

Phase 1

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
CompletedNCT00558571
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2008-01-31Updated: 2014-08-07

Phase 2

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
CompletedNCT01011868
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2009-11-30Updated: 2014-09-30

Phase 3

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
CompletedNCT01131676
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2010-07-31End: 2015-04-30Updated: 2016-05-16
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
CompletedNCT01422876
Boehringer IngelheimDiabetes Mellitus, Type 2
Start: 2011-08-31End: 2013-09-30Updated: 2015-04-02

Related Papers

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.
2024-07-118 citations
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial.
2024-02-094 citations
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.
2023-12-181 citations
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Stroke2023-07-149 citations
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Frontiers in Pharmacology2022-08-3010 citations
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.
2021-12-2415 citations
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
American Journal of Kidney Diseases2021-11-0645 citations
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPA‐REG OUTCOME</scp> trial
Diabetes Obesity and Metabolism2021-09-2459 citations
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes
JACC Heart Failure2021-07-2615 citations
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
2021-06-1525 citations
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Journal of the American Heart Association2021-03-2319 citations
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
2020-12-0147 citations
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
2020-11-2616 citations
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
2020-10-1327 citations
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
Clinical Journal of the American Society of Nephrology2020-09-2979 citations
Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Journal of the American Heart Association2020-09-0671 citations
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME
Journal of Hypertension2020-06-2622 citations
Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc</i> Analysis of the EMPA-REG OUTCOME Trial
American Journal of Hypertension2020-04-2936 citations
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
2020-01-0113 citations
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Nephrology Dialysis Transplantation2019-08-1229 citations

18 more papers not shown